AVROBIO, Inc. Forecasted to Post FY2027 Earnings of ($0.13) Per Share (NASDAQ:AVRO)

AVROBIO, Inc. (NASDAQ:AVRO – Get Rating) – Analysts at Wedbush issued their FY2027 EPS estimates for AVROBIO in a research note issued to investors on Thursday, May 11th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.13) per share for the year. The consensus estimate for AVROBIO’s current full-year earnings is ($1.75) per share.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of AVROBIO in a report on Friday, March 24th.

AVROBIO Price Performance

AVROBIO stock opened at $0.64 on Monday. The firm has a fifty day moving average of $0.98 and a 200-day moving average of $0.96. The firm has a market capitalization of $28.06 million, a P/E ratio of -0.26 and a beta of 1.59. AVROBIO has a 52-week low of $0.56 and a 52-week high of $1.93. The company has a quick ratio of 7.62, a current ratio of 7.62 and a debt-to-equity ratio of 0.20.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC boosted its stake in AVROBIO by 20.4% during the 1st quarter. Acadian Asset Management LLC now owns 1,770,147 shares of the company’s stock valued at $1,768,000 after acquiring an additional 300,255 shares during the last quarter. GMT Capital Corp lifted its position in shares of AVROBIO by 31.7% in the 1st quarter. GMT Capital Corp now owns 4,357,859 shares of the company’s stock worth $4,358,000 after buying an additional 1,048,000 shares during the last quarter. Bailard Inc. lifted its position in shares of AVROBIO by 76.4% in the 1st quarter. Bailard Inc. now owns 45,492 shares of the company’s stock worth $45,000 after buying an additional 19,700 shares during the last quarter. Virtu Financial LLC bought a new position in shares of AVROBIO in the 1st quarter worth about $40,000. Finally, FNY Investment Advisers LLC bought a new position in shares of AVROBIO in the 1st quarter worth about $26,000. 55.74% of the stock is currently owned by institutional investors.

About AVROBIO

(Get Rating)

Avrobio, Inc engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm’s clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis.